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SUMMARY
The Rb/E2F pathway regulates the expression of genes essential for cell proliferation but that also trigger ap-
optosis. During normal proliferation, PI3K/Akt signaling blocks E2F1-induced apoptosis, thus serving to bal-
ance proliferation and death. We now identify a subset of E2F1 target genes that are specifically repressed by
PI3K/Akt signaling, thus distinguishing the E2F1 proliferative or apoptotic function. RNAi-mediated inhibition
of several of these PI3K-repressed E2F1 target genes, including AMPKa2, impairs apoptotic induction by
E2F1. Activation of AMPKa2 with an AMP analog further stimulates E2F1-induced apoptosis. We also show
that the presence of the E2F1 apoptotic expression program in breast and ovarian tumors coincides with
good prognosis, emphasizing the importance of the balance in the E2F1 proliferation/apoptotic program.INTRODUCTION
The control of cellular proliferation, including the entry from qui-
escence (G0) into the cell cycle (G1) and passage into the DNA
replication (S) phase, is tightly regulated by cell size, mitogenic
stimulation, and absence of signals that block proliferation.
The retinoblastoma (Rb) protein is now recognized as a pivotal
regulator of entry into the cell cycle and is controlled by the
activity of upstream cyclin-dependent kinases (CDKs) that are
activated during the transition from G0 to G1. Importantly, dis-
ruption of various components of this control pathway leads to
deregulated proliferation that underlies the development of
many forms of human cancer (Bosco and Knudsen, 2007; John-
son and DeGregori, 2006).
Numerous studies have established that Rb control of E2F
transcription factor function is crucial for its control of cell-cycle
progression and tumorigenesis. E2Fs comprise a family of eight
transcription factors that can be classified into different groups
based on domain conservation and transcriptional activity (Att-
wooll et al., 2004; DeGregori and Johnson, 2006). For example,
E2F1, E2F2, and E2F3 are generally transcriptional activators
of genes important for cell-cycle progression and nucleotide
synthesis like Cdc6, Cyclin E, and dihydrofolate reductase. OtherE2Fs, like E2F4, E2F5, and E2F6, generally function as repres-
sors of E2F gene expression. The recently discovered E2F7
and E2F8 genes form a separate group with antiproliferative
function (Christensen et al., 2005; Logan et al., 2005; Maiti
et al., 2005). The interaction of Rb inhibits E2F transcriptional ac-
tivity, and hyperphosphorylation of Rb by Cdks during cell-cycle
progression causes Rb to be released from E2F inhibition, allow-
ing transcriptional activation of cell-cycle genes. Given the
pervasive role of Rb pathway mutations and, thus, E2F1 dere-
gulation in human cancer, understanding the mechanisms
underlying distinct cellular outcomes by E2Fs is critical to devel-
oping increasingly focused anticancer therapeutics.
Additional work has pointed to a central role of the Rb/E2F
pathway in balancing the cellular decision of proliferation and ap-
optosis, first highlighted through the analysis of DNA tumor virus
oncoproteins (Ahuja et al., 2005; Berk, 2005; O’Shea, 2005). The
inactivation of Rb function by viral proteins such as E1A, T anti-
gen, and E7 that induces cells to enter S phase also triggers p53-
dependent apoptosis (de Stanchina et al., 1998). This apoptotic
process is then blocked through the action of an additional set
of viral proteins that inhibit p53 activity. Further work has high-
lighted the role of E2F proteins, particularly E2F1, in forming
the link between the deregulation of Rb pathway activity andSIGNIFICANCE
E2F1 has been shown to induce both proliferation and apoptosis. We now show that PI3K/Akt signaling regulates the bal-
ance of these events by specifically blocking expression of genes in the E2F1 apoptotic program, but not the proliferative
program.We further show that an alteration in the balance of the E2F1 program coincideswith poor prognosis in both breast
and ovarian cancer, emphasizing the importance of these events for a clinical cancer phenotype.Cancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc. 11
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Hallstrom and Nevins, 2003; Kowalik et al., 1995, 1998; Qin
et al., 1994; Shan and Lee, 1994; Wu and Levine, 1994).
Given the fact that E2F1 does accumulate when cells are stim-
ulated to grow and is required for the initial entry into the cell cy-
cle, the capacity of E2F1 to induce apoptosis must be blocked in
order for cells to complete a normal proliferative cycle. We have
previously demonstrated that E2F1-induced apoptosis can be
blocked by survival pathways induced following normal cell
growth. Additional analysis delineated a role for PI3K and Akt
signaling in the abrogation of E2F1 apoptosis induction (Hall-
strom and Nevins, 2003). PI3K and Akt are widely involved in cel-
lular apoptosis inhibition by phosphorylating and regulating the
activity of apoptotic gene products such as BAD, Caspase-9,
and Mdm2 (Cardone et al., 1998; Datta et al., 1997; del Peso
et al., 1997). We have now further analyzed the ability of
growth-factor-activated PI3K signaling to directly regulate
E2F1 transcriptional output and apoptosis induction. We show
here that a subset of previously unidentified E2F1 target genes
is repressed by a serum-activated PI3K signaling pathway.
This differs from the expression profile of classical cell-cycle
E2F target genes, which are typically activated, not repressed,
by mitogenic stimulation. Through shRNA-targeted degradation,
we have identified a role for several of these PI3K-repressed
E2F1 targets in apoptosis induction. One of these proapoptotic
targets, AMPKa2, a sensor of cellular energy levels and a compo-
nent of the PI3K signaling pathway, is induced by E2F1 under
growth factor starvation but repressed during normal prolifera-
tion. Activation of AMPKa2 with AICAR, an AMP analog, further
stimulates E2F1-induced apoptosis. Examination of E2F1 target
gene levels in breast and ovarian tumors indicate that reduced
expression of these targets is observed in patients that display
significantly poorer survival outcomes.
RESULTS
Identification of E2F1 Target Genes Repressed
by Serum-Activated PI3K Signaling
Our previous work has demonstrated a role for serum-activated
PI3K and Akt signaling in abrogating the E2F1 triggered p53 in-
duction and apoptotic response that normally occurs in cells de-
prived of growth factors (Figure 1A) (Hallstrom and Nevins,
2003). This is not simply an effect on E2F1 activity since there
is no variation in the level of E2F1 protein as a function of serum
or PI3K inhibition (Figure 1B). The antiapoptotic effect of PI3K
could at least partially be explained by posttranslational modifi-
cation of key apoptotic proteins mediated by Akt. Alternatively,
growth-factor-activated PI3K signaling may also repress activa-
tion of E2F1 apoptotic target genes. We explored this possibility
using DNA microarray analysis of quiescent REF52 rat fibro-
blasts that had been infected with control or E2F1 adenovirus
in the presence or absence or 10% serum or LY294002,
a PI3K inhibitor. Analysis was done in duplicate to reduce the
background that would arise from using a single data point.
We normalized the gene expression data using the robust mul-
tiarray average (RMA) algorithm and usedGene Cluster 3.0 to or-
ganize the results based on unsupervised hierarchical clustering.
Results were visualized using Java TreeView and are displayed
based on the normalized intensity with green representing lower12 Cancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc.relative gene expression and red indicating higher expression
(Figure 1C). A total of 772 E2F1 targets that displayed at least
a 2-fold increase in expression based on MAS5 data were clus-
tered. Comparison of lane 1 (control) with lane 4 (E2F1) indicates
that each of these are E2F1-induced target genes. Addition of
serum has no major effect on many of these targets in control
cells although some of these genes display a modest serum in-
duction (lane 1 versus lanes 2). The expression of the majority
of E2F1 target genes remains high when cells are stimulated
with serum (Lane 5, red side bar). The red bar indicates some
of the E2F targets whose expression is not repressed by serum
activated pathways. These genes are shown in the enlarged heat
map to the right. The E2F genes in this cluster are representative
of the most well-known proliferative targets involved in G1/S and
G2/M cell-cycle progression. These genes are also displayed in
Table 1 based on their level of maintained or heightened expres-
sion in the presence of serum. Classification of these genes us-
ing GO annotations indicates that these genes are overwhelm-
ingly associated with cell cycle and mitosis, and the majority of
the genes contain predicted E2F binding sites in their promoters
(see Table S1A available with this article online).
The results also indicate that serum inhibits the expression of
a significant number of the E2F1 target genes (Figure 1C, lane 5,
green sidebar). Many of these have not previously been de-
scribed as E2F targets. These genes comprise transcription
factors, signaling pathway G-proteins/kinases, biosynthetic en-
zymes, and transporters. Genes whose expression is blocked
by PI3K activity based on fold-change analysis are displayed in
Table 2. GO annotation analysis indicates that these genes serve
pleiotropic functions but also suggests that E2F binding sites are
highly represented in the promoters of these genes (Table S1B).
Further analysis revealed that the serum-mediated repression of
the E2F1 targets required PI3K as indicated by the fact that inhi-
bition of PI3K activity with LY294002 restored expression
(Figure 1C, lane 6). These results suggest that a category of
E2F1 target genes are only induced in conditions lacking PI3K
activity.
We verified the expression pattern of several of the PI3K-re-
pressed E2F target genes, including PRKAA2/AMPKa2, Nr4a3,
Cyp26b1, and p27KIP1, using quantitative real-time PCR normal-
izing to internal GAPDH levels. Ref52 cells were treated as indi-
cated in Figure 2A, and mRNA was isolated for qRT-PCR analy-
sis at 40 hr postinfection, the same point RNA was isolated for
apoptosis and affymetrix analysis. The expression level of each
gene in quiescent, CMV infected cells was set to 1, and all other
results are compared with this value and reported as fold induc-
tions. As shown in Figure 2A, each of these four genes is induced
by E2F1 in quiescent Ref52 cells ranging in fold inductions from
2.5 for p27KIP1 to 65-fold induction for Cyp26b1. Addition of se-
rum significantly inhibits induction of these E2F targets, with re-
ductions by serum ranging from a 57% to 75%. This repression
is dependent on PI3K activity, because addition of LY294002,
a PI3K inhibitor, restores E2F1-dependent expression of each
of these genes.
The chemical inhibitor LY294002 can affect additional targets
besides PI3K, so we determined whether PI3K directly inhibits
E2F1-dependent activation of AMPKa2, Nr4a3, and p27KIP1.
To answer this question, we infected quiescent Ref52 cells
with E2F1 alone or E2F1 coinfected with PI3K, isolated mRNA
Cancer Cell
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Genes Repressed by Serum-Activated
PI3K Signaling
(A) Our previous studies have identified a role for
PI3K signaling in blocking E2F1-induced apopto-
sis, although the mechanisms underlying this inhi-
bition are unclear. Ref52 cells were infected with
with equal multiplicities of infection (25 moi) of
control or E2F1-expressing adenovirus. Cells
were treated with low serum (0.25%) designated
with ‘‘’’, high serum (10%) indicated by ‘‘+’’, or
high-serum media containing the PI3K inhibitor
LY294002 following infection. E2F1 induces apo-
ptosis in quiescent cells, and this apoptosis is
blocked by a serum-activated PI3K signaling
pathway.
(B) Ref52 cells treated by serum deprivation,
serum stimulation, or serum stimulation with
LY294002 were infected with equal multiplicities
of infection (moi) and harvested for immunoblot
analysis 24 hr postinfection. Expression levels of
E2F1 protein are unaffected by PI3K expression,
treatment with serum, or by the PI3K inhibitor
LY294002.
(C) We tested whether PI3K blocks expression of
potentially apoptotic E2F1 target genes using
Affymetrix analysis. Cells were treated as outlined
in (A) and harvested 40 hr postinfection for RNA
extraction. Equal amounts or RNA were analyzed
using Affymetrix RAE230A arrays. Affymetrix
gene expression data were normalized across
chips using the robust multiarray average (RMA)
algorithm and analyzed using unsupervised hierar-
chical clustering. Green shading represents low
gene expression, whereas red shading indicates
higher expression. Only the E2F targets displaying
aminimum 2-fold induction by E2F1 in quiescence
(based onMas5 data) were included for clustering.
Each gene is induced by E2F1 in low-serummedia
(lanes 1 and 4). Most E2F1 targets remain similarly
expressed in high serum media (lane 5); however,
a subset is no longer induced by E2F1 in high
serum (indicated by the green bar). This repression
by serum is largely dependent on PI3K activity
because expression of most of these genes is
restored when PI3K function is disabled with
LY294002 (lane 6). Both classes of E2F1 targets
are displayed enlarged at the right.24 hr postinfection, and measured target gene expression using
real-time PCR. Coinfection of PI3K reduced E2F1-dependent
expression of AMPKa2 by 52%, Nr4a3 by 58%, and p27KIP1
by 41%, indicating that PI3K can directly influence repression
of these E2F target genes. We also tested PI3K effect on
Cyp26b1 but did not observe reduction of its E2F1-dependent
expression by PI3K.
PI3K-Repressed Targets Mediate
E2F1-Induced Apoptosis
Previous work has established a clear role for the E2F transcrip-
tion factors in the regulated expression of genes required for pro-
liferation. The majority of these genes are positively regulated in
response to serum-stimulated growth. This includes a subset of
the genes induced by E2F1 whose expression is independent
of PI3K activity. In contrast, our results now also identify a subsetof E2F1 target genes that are repressed, not activated, in response
to serum-stimulated growth. Because of this unique expression
pattern, we tested whether these growth-repressed E2F targets
facilitate apoptosis induction by targeting seven of these genes
for shRNA-mediated knockdown in U2OS (human-osteosar-
coma-derived) cells. Genes were selected for targeted knock-
down based on level of induction by E2F1 in serum-deprived
Ref52 cells and the extent of repression of these genes by se-
rum. As controls, we also generated three independent U2OS
cell lines infected with control vector retrovirus. After puromycin
selection of retrovirus transduced cells, gene knockdown effi-
ciency was measured using real-time PCR (Figure S1A). We
tested the effects of target gene knockdown on E2F1 apoptosis
induction by depriving cells of serum for 48 hr, infecting with
E2F1-expressing adenovirus, and harvesting cells 40 hr postin-
fection for caspase-3 flow cytometry assays. Results areCancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc. 13
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Gene Symbol Gene Title E2F1 Induction E2F Exp. with Serum
Lmnb1 lamin B1 5.64 686.6%
Bard1 BRCA1 associated RING domain 1 12.62 441.1%
Kif2c kinesin family member 2C 8.11 285.4%
LOC690771 Hypothetical protein LOC690771 4.6 229.8%
Nefh neurofilament, heavy polypeptide 6.15 221.2%
Mcam melanoma cell adhesion molecule 5.08 220.7%
Ribc1 RIB43A domain with coiled-coils 1 5.37 219.7%
Hrmt1l3 heterogeneous nuclear ribonucleoprotein methyltransferase-like 3 5.97 218.9%
Pttg1 pituitary tumor-transforming 1 6.13 218.2%
Rrbp1 ribosome binding protein 1 homolog 180kDa (dog) 10.34 218.0%
Slc35e1 Solute carrier family 35, member E1 5.11 214.9%
Ccnb1 cyclin B1 6.2 205.6%
Top2a topoisomerase (DNA) 2 alpha 11.57 194.9%
Bub1b budding uninhibited by benzimidazoles 1 homolog, beta 32.15 193.2%
Cdc20 cell division cycle 20 homolog (S. cerevisiae) 4.51 192.1%
Dhrs9 dehydrogenase/reductase (SDR family) member 9 7.61 189.3%
Cask calcium/calmodulin-dependent serine protein kinase 4.55 188.8%
RGD1308747 hypothetical protein FLJ10156 5 185.5%
Kif20a kinesin family member 20A 11.55 172.9%
Top2a topoisomerase (DNA) 2 alpha 13.02 171.9%
Ccnb1 cyclin B1 5.5 170.6%
Nef3 neurofilament 3, medium 8.15 170.3%
RGD1563319 RIKEN cDNA 6330512M04 gene 6.35 166.1%
Brca2 breast cancer 2 14.17 160.0%
Fshprh1 FSH primary response 1 9.51 158.6%
Ptp4a3 protein tyrosine phosphatase 4a3 6.77 158.2%
Obp3 Alpha-2u globulin PGCL1 13.83 157.4%
RGD1566097 Anillin 5.54 155.7%
Ccnb2 cyclin B2 9.58 155.2%
Spag5 sperm associated antigen 5 5.75 154.5%
Homer1 homer homolog 1 (Drosophila) 7.61 152.8%
Spbc24 spindle pole body component 24 homolog 35.48 150.7%
Traf4af1 TRAF4 associated factor 1 31.54 150.0%
LOC685433 ecotropic viral integration site 2A 6.02 148.1%
Iqgap3 IQ motif containing GTPase activating protein 3 10.08 147.3%
LOC497083 XK-related protein 5 11.44 145.6%
Nfyb nuclear transcription factor-Y beta 10.48 143.8%
Cdc25b cell division cycle 25 homolog B 5.6 143.2%
Lmnb1 lamin B1 6.28 141.8%
Hipk3 homeodomain interacting protein kinase 3 18.8 138.1%
Tacc3 transforming, acidic coiled-coil containing protein 3 6.55 136.6%
Cldn2 Claudin 2 6.33 135.7%
Melk maternal embryonic leucine zipper kinase 8.46 135.3%
Cdca8 cell division cycle associated 8 14.52 135.2%
Racgap1 Rac GTPase-activating protein 1 9.53 135.1%
Foxm1 forkhead box M1 30.45 134.4%
Rims2 regulating synaptic membrane exocytosis 2 4.86 131.7%
Cdkn3 cyclin-dependent kinase inhibitor 3 14.54 131.5%
Gbp2 guanylate nucleotide binding protein 2 13.63 130.9%
RGD1562596 mKIAA0159 protein 12.25 130.7%14 Cancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc.
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Gene Symbol Gene Title E2F1 Induction E2F Exp. with Serum
LOC684513 SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin c2 isoform b
7.09 130.5%
Slc38a1 solute carrier family 38, member 1 5.52 130.4%
Cdc2a cell division cycle 2 homolog A (S. pombe) 8.35 128.6%
RGD1565889 citrin 4.73 127.0%
Fabp5 fatty acid binding protein 5, epidermal 10.2 126.5%
Adk adenosine kinase 5.14 126.3%
Espl1 extra spindle poles like 1 (S. cerevisiae) 15.79 125.3%
E2F1 induction refers to fold induction by E2F1 compared with control in serum-deprived REF52 cells. These genes are all induced at least 4.5-fold,
rather than 3.5-fold, induction as in Table 2, since many more genes were induced than were repressed by serum. The column ‘‘E2F Exp. with Serum’’
compares E2F1-dependent expression in serum-containing media with expression levels in serum-deprived media.displayed as the percent apoptosis induction relative to the aver-
age combined active caspase-3 measurements of the three
vector control cell lines.
We found that knockdown of two of these E2F targets, CXCR4
and MAP4K2, had no effect on E2F1 apoptosis induction
(Figure 3A), although these genes were degraded by shRNA
(Figure S1A). In contrast, targeted degradation of other E2F
targets impaired apoptosis induction to varying degrees. For
example, two different shRNAs targeting PRKAA2/AMPKa2,
a key regulator of metabolic pathways in response to reduced
cellular energy levels, inhibited E2F apoptotic activity by 70%
and 50%. Reduction of Cyp26b1, an enzymatic regulator of all-
trans retinoic acid metabolism, inhibited E2F1 apoptosis induc-
tion by 50%. We find that two different shRNA constructs that
target Nr4a3 (Nuclear receptor subfamily 4, group A, member 3),
a transcription factor that can promote apoptosis in various con-
texts, leads to a reduction in E2F1 induction of apoptosis by 40%
or 48%. The gene MLLT3 (myeloid/lymphoid or mixed lineage
leukemia, translocated to 3) inhibits E2F1 apoptosis by 50%
when degraded by shRNA. Finally, shRNA targeting of the un-
characterized gene RBPMS (RNA-binding protein with multiple
splicing sites) inhibited E2F1 apoptosis by 50%.
Vector control cells were susceptible to E2F1-induced apo-
ptosis and, consequently, were almost completely killed and
cleared from the plate (Figure 3B). shRNA gene knockdowns
that impaired caspase-3 cleavage also permitted cells to resist
apoptosis and survive in these plate assays (AMPKa2,
Cyp26b1, Nr4a3, Mllt3, and RBPMS). The apoptosis sensitive
shRNA knockdown cell lines (Cxcr4 and MAP4K2) were also
susceptible to E2F1 killing on plate assays and were significantly
cleared off the plate. To further analyze the role of AMPKa2 in
mediating E2F1-induced apoptosis, we targeted AMPKa2 for
shRNA degradation by stable retroviral integration in 3 pools of
human diploid fibroblast cells (IMR90). We then deprived control
and knockdown cells of serum, infected with E2F1, and mea-
sured effects on cell killing by caspase-3 cleavage analysis.
E2F1 was expressed equivalently across the experimental cell
lines. As shown in Figure 3C, depletion of AMPKa2 renders
human fibroblasts resistant to E2F1-induced cell killing. These
results confirmed that the genetic connection between E2F1
and AMPKa2 was conserved in tumor (U2OS) and nontumor
(IMR90) cell lines. We also observe induction of AMPKa2,
Cyp26b1, and Nr4a3 by E2F1 in U2OS and IMR90 cells, furtherstrengthening the genetic connection of these genes with E2F1
(Figure S1B).
Synergistic Activation of E2F1 Apoptosis by AMPKa2
Coexpression or AMPK Activation with AICAR
AMPKa2 is an evolutionarily conserved regulator of cellular
energymetabolic pathways in response to ATP and nutrient dep-
rivation (Shaw, 2006; Tower and Hardie, 2007). Ectopic AMPKa2
expression does not induce apoptosis in IMR90 cells on its own,
but when coinfected with levels of E2F1 subthreshold for
apoptosis induction, we observe a synergistic activation of
apoptosis by this combinatorial treatment (Figure 4A).
Because E2F1 induction of AMPKa2 during nutrient-poor con-
ditions promotes apoptosis, we predicted that a pharmacologic
activator of AMPKa2 should further enhance E2F1 apoptosis
induction. We tested this hypothesis using AICAR, an AMP ana-
log that activates AMPK complexes (Sullivan et al., 1994). Treat-
ment of control infected U2OS cells with AICAR does not induce
apoptosis (Figure 4B). Infecting U2OS cells with low levels of
E2F1 caused only a modest increase in caspase-3 cleavage.
Further stimulation of E2F1-infected U2OS cells with the drug
AICAR, however, led to a 2.5-fold increase in apoptosis com-
paredwith E2F1 infection alone. Todetermine the extent towhich
this enhanced apoptosis is dependent on the presence of
AMPKa2, we repeated these experiments in cells depleted for
AMPKa2 levels by shRNA. In this cellular context, we find that co-
treatment with E2F1 and AICAR no longer enhances apoptosis,
indicating heavy dependence on AMPKa2 for this outcome. We
also observed that AICAR does not enhance E2F1 apoptosis in-
duction in cellular contexts where Cyp26b1 or Nr4a3 have been
degraded by shRNA. This may indicate that expression of these
additional E2F1 apoptotic targets is required in conjunction
withAICARactivation of AMPKa2 tobring cells over the threshold
required to commit to the apoptotic program.
Impact of the E2F1 Apoptotic Program
on Human Cancer Phenotypes
The results we present here point to a role for PI3K activity in
defining the balance of E2F1-mediated proliferation or apoptotic
function. Given the predominant role of Rb/E2F and PI3K path-
way activities in human cancer and in light of the widely held
view that disabling oncogene-induced apoptosis is a common
aspect of many cancers, we asked whether the PI3K-repressedCancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc. 15
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Gene Symbol Gene Title E2F1 Induction E2F Exp. with Serum
RBPMS RNA-binding protein gene with multiple splicing 11.62 5.0%
Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit 10.03 6.5%
LOC682245 Acylphosphate phosphohydrolase 39.5 8.9%
Hist1h2bp histone 1, H2bp 5.14 9.7%
LOC493574 notch1-induced protein 5.42 10.0%
Pdzd4 PDZ domain containing 4 3.72 11.0%
P22k15 cystatin related protein 2 5.25 11.9%
Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 61.86 12.1%
Gnao Guanine nucleotide binding protein, alpha o 12.18 12.4%
Prlph prolactin-like protein H 7.38 15.3%
Sfn stratifin 4.66 15.8%
Limk1 LIM motif-containing protein kinase 1 6.88 17.2%
Ugt2b3 UDP glycosyltransferase 2 family, member 3 6.5 18.5%
RGD1559826 nectin 4 6.96 20.0%
Septin 4 septin 4 5.88 21.3%
RGD1311456 RIKEN cDNA B230380D07 12.75 21.3%
Plxdc2 plexin domain containing 2 3.5 21.7%
RGD1307569 Protein C21orf63 homolog precursor 7.77 22.4%
Mllt3 myeloid/lymphoid or mixed-lineage leukemia,translocated to, 3 8.45 24.2%
LOC683830 Calreticulin precursor (CRP55) (Calregulin) (HACBP) (ERp60) 3.97 24.2%
Nr2f1 nuclear receptor subfamily 2, group F, member 1 5.67 24.7%
Ptpn7 protein tyrosine phosphatase, non-receptor type 7 6.52 25.5%
RGD1311132 RIKEN cDNA E430013E20 gene 6.49 25.7%
Map4k2 mitogen activated protein kinase kinase kinase kinase 2 22.39 26.6%
Ces2 carboxylesterase 2 (intestine, liver) 4.56 27.3%
RGD1310271 hypothetical protein MGC45873 11.86 27.7%
Tnc Tenascin C /// Tenascin C 6.09 27.8%
Cbx7 chromobox homolog 7 6.08 28.0%
Dlgap2 Discs, large (Drosophila) homolog-associated protein 2 9.47 28.6%
Fxyd4 FXYD domain-containing ion transport regulator 4 5.17 29.3%
Slc21a13 solute carrier family 21, member 13 10.17 29.5%
RGD1562284 Glutaminyl-peptide cyclotransferase precursor (QC) 10.91 30.2%
Cml5 camello-like 5 7.59 32.9%
Nos3 nitric oxide synthase 3, endothelial cell 4.18 34.4%
Gprc5b G protein-coupled receptor, family C, group 5, member B 3.66 34.9%
RGD1562847 paired immunoglobin-like type 2 receptor alpha 3.81 35.3%
Ybx2 Y box protein 2 8.86 35.9%
Mal2 mal, T-cell differentiation protein 2 3.77 37.6%
Kng1 kininogen 1 4.12 38.8%
Magi3 membrane associated guanylate kinase, WW, and PDZ domain 3 6.01 39.3%
RGD1563612 testhymin 3.81 40.3%
Hspbap1 Hspb-associated protein 1 4.12 40.7%
Nubpl nucleotide binding protein-like 11.26 40.7%
Prg-2 plasticity-related protein PRG-2 23.65 41.4%
Mylk2 myosin light chain kinase 2, skeletal muscle 3.94 41.6%
Elavl4 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 3.67 41.9%
Arhgef11 Rho guanine nucleotide exchange factor (GEF) 11 4.88 42.1%
LOC680097 germinal histone H4 gene 7.49 42.2%
Rtn1 reticulon 1 6.06 42.6%
LOC303730 chromobox homolog 2 41.38 43.5%16 Cancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc.
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Gene Symbol Gene Title E2F1 Induction E2F Exp. with Serum
Bst1 bone marrow stromal cell antigen 1 5.46 43.6%
Nr4a3 nuclear receptor subfamily 4, group A, member 3 6.24 43.8%
Fmr1 fragile X mental retardation syndrome 1 homolog 3.62 44.5%
Tada1l transcriptional adaptor 1 (HFI1 homolog, yeast) like 4.13 44.5%
Rbp2 retinol binding protein 2, cellular 45.1 45.0%
E2F1 induction refers to the fold induction of the gene in REF52 cells infectedwith E2F1, compared with expression in control infected cells deprived of
serum. Only the genes induced at least 3.5-fold are displayed here. The second column, labeled ‘‘E2F Exp. with Serum,’’ compares the % expression
by E2F1 in serum-containing media compared with E2F1-dependent expression in serum-deprived media. These genes were identified in Microsoft
Excel based solely on fold induction and repression and are not the full list identified by GeneCluster analysis.E2F1 target gene signature displays a pattern of expression in
human cancers in relation to clinical outcomes. We used the list
of E2F1 target genesderived fromclustering analysis in Figure 1C
whose expression is not reduced by PI3K (cluster marked by red
bar) and the genes whose expression is repressed by serum ac-
tivated PI3K signaling (cluster indicated by the green bar). We
next identified the human U133A Affymetrix probes correlating
with the RAE230A genes (PI3K-repressed and -nonrepressed)
and U133A probe set information from Affymetrix. The expres-
sion values of these E2F genes were then extracted from four dif-
ferent human cancer microarray experiments—three breast can-
cer tissue data sets (GSE1456, GSE4922, and GSE2034) and an
ovarian cancer data set (GSE3149) (Bild et al., 2006; Ivshina et al.,
2006; Pawitan et al., 2005; Wang et al., 2005). Each of these ex-
periments used U133A Affymetrix platform, and we normalized
expression data across all chips using the robustmultiarray aver-
age (RMA) algorithm. RMA data was gene- and array-centered
using Gene Cluster 3.0 and clustered hierarchically by average
linkage. Clustered results were visualized using Java TreeView.
Unsupervised hierarchical clustering of both the breast and
ovarian cancer data sets revealed a similar pattern of E2F1 pro-liferative and apoptotic gene expression. The red and green
color bar located to the right of the cluster displays the location
of clustered PI3K-repressed (red) and PI3K-nonrepressed
(green) E2F1 target genes. In general, the PI3K-nonrepressed
targets and the PI3K-repressed genes were mutually exclusive
in their expression levels (Figures 5A–5C and Figure S2). Further-
more, both breast and ovarian tumors are separated into two dis-
tinct subgroups based on the expression of these E2F1 target
genes. The first group of tumors, designated above by red-
shaded clustering, in general display reduced levels of the
PI3K-nonrepressed E2F1 targets and higher relative levels of
the PI3K-repressed (apoptotic) E2F1 target genes. The second
group of tumors, marked above with green-shaded clustering,
display an inverse expression phenotype, expressing high levels
of E2F proliferative targets and reduced levels of PI3K-repressed
E2F1 target genes.
Similar to previous studies that have used expression signa-
tures of oncogenic pathway activation to predict the state of
the pathway in tumors, we have applied the PI3K gene expres-
sion signature to the breast and ovarian cancer data sets to
predict PI3K pathway activity in these tumors (Bild et al.,Figure 2. Expression of Selected PI3K-
Repressed E2F1 Targets Using Quantitative
Real-Time PCR
(A) mRNA expression levels of AMPKa2 (Prkaa2),
Nr4a3, Cyp26b1, and p27KIP1 were measured
using quantitative real-time PCR in cells treated
with or without E2F1 infection, high serum, or the
PI3K inhibitor LY294002. RNA was isolated 40 hr
postinfection, the same time point used to isolate
RNA for array experiments. Results were normal-
ized to GAPDH levels and are displayed relative
to the expression of the gene in serum-deprived
cells infected with control adenovirus and repre-
sent three independent experiments. Error bars
here and in (B) represent mean ± SD.
(B) RT-PCR measurements of AMPKa2, Nr4a3,
and p27KIP1 mRNA levels were taken in E2F1-
infected cells either with or without PI3K coinfec-
tion 24 hr postinfection and normalized to GAPDH
levels. Expression levels of each gene in PI3K
noninfected cells was set to 100% and used to
compare the effects of PI3K repression of gene
expression, thus emphasizing PI3K repression
rather than relative induction by E2F1. These
experiments were done using low (0.25%) serum
media and are representative of three independent
experiments.Cancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc. 17
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Repression of E2F1 Apoptosis by PI3K in CancerFigure 3. Select PI3K-Repressed Targets Mediate E2F1-Induced
Apoptosis
(A) Selected PI3K-repressed E2F1 genes were targeted for shRNA-mediated
degradation in U2OS cells to assess their role in E2F1 apoptosis induction.
Control and knockdown cell lines were deprived of serum, infected with
E2F1, and apoptosis measurements were compared between knockdown
and control lines. Results are presented as the percent apoptosis observed
in knockdown lines relative to control cells and are indicative of a minimum
of three independent experiments. Genes displaying more than one colored
bar were degraded with independent shRNA constructs that target the
mRNA in distinct locations. Error bars represent mean ± SD.
(B) The same U2OS cell lines were deprived of serum for 48 hr, infected with
E2F1, and photographed 72 hr postinfection. Whereas vector control cell lines
were almost completely killed by apoptosis after E2F1 infection, knockdown of
select PI3K-repressed targets impaired E2F1 apoptotic killing, allowing
survival and cell accumulation on plates. Scale bar, 10 mm.18 Cancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc.2006). This analysis is displayed as a color bar below the gene
clustering where cool colors (blue) represent low predicted acti-
vation and warm colors (red) refer to high predicted activation of
PI3K. This analysis separates both breast and ovarian tumors
into two clusters with either quite low or high predicted PI3K ac-
tivation. Interestingly, the tumors with high predicted PI3K activ-
ity generally display the lowest expression of the PI3K-repressed
E2F1 target genes. Conversely, breast and ovarian tumors with
low predicted PI3K activity in general express higher levels of
the PI3K-repressed target genes. Advanced stage 3 tumors
cluster predominantly with tumors that poorly express PI3K-re-
pressed E2F1 target genes, whereas stage 1 and stage 2 tend
to cluster with tumors that highly express these genes. Further-
more, patients with either breast or ovarian tumors that display
reduced levels of these PI3K-repressed E2F1 genes show signif-
icantly worse prognosis of patient survival (Figures 5A–5C) or
higher recurrence rates (Figure S2) than patient expressing
high levels of these genes.
Discussion
The Rb/E2F pathway regulates the expression of gene products
that facilitate transition through various stages of the cell cycle.
These include both DNA replication genes that function during
the G1/S transition and genes controlling chromosome
(C) IMR90 cells, a wild-type human fibroblast line, were infected with retrovirus
expressing three distinct AMPKa2-targeting shRNA constructs. These lines
were tested for AMPKa2 knockdown, deprived of serum, infected with
E2F1, and photographed 72 hr postinfection. Knockdown of AMPKa2 in
IMR90 cells, like in U2OS cells, also impaired E2F1 apoptosis induction. Scale
bar, 10 mm.
Figure 4. Synergistic Activation of E2F1 Apoptosis by AMPKa2
Coexpression or AMPK Activation with AICAR
(A) IMR90 cells were infected with adenovirus expressing AMPKa2, E2F1 at
levels below the threshold to induce apoptosis, or a combination of AMPKa2
and E2F1. Neither AMPKa2 nor E2F1 individually induced apoptosis in IMR90,
but the combination of E2F1 and AMPKa2 significantly enhanced cellular
apoptosis. Error bars here and in (B) represent mean ± SD.
(B) U2OS cells were deprived of serum and infected with control or subapop-
totic threshold levels of E2F1 (0.5 MOI) and treated with vehicle or AICAR, an
AMP-analog activator of AMPKa2. AICAR does not promote apoptosis in
control cells but strongly enhances apoptosis in cells infected with E2F1.
shRNA knockdown of AMPKa2 significantly impairs this enhancement of
E2F1 induced apoptosis by AICAR.
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the cell cycle. Various studies have suggested a complex role
for E2F1, contributing to the control of both cellular proliferation
and cell fate. For instance, both E2F1 and E2F3 are required for
cell-cycle entry, but only E2F3 is required for continued cell pro-
liferation (Kong et al., 2007). Unlike the other activator E2Fs,
E2F1 also responds to various cellular stresses. For example,
DNA damage-induced activation of ATM, ATR, and Chk2 leads
to specific phosphorylation and accumulation of E2F1, but not
E2F2 or E2F3 (Lin et al., 2001; Stevens et al., 2003). It is also clear
that Rb/E2F controls transcription of genes like p14ARF, p73,
Apaf1, Caspases, Chk2, and BH3-only proteins that contribute
to the induction of cellular apoptosis (Bates et al., 1998; Croxton
et al., 2002; Hershko and Ginsberg, 2004; Irwin et al., 2000; Lissy
et al., 2000; Moroni et al., 2001; Nahle et al., 2002; Rogoff et al.,
2002, 2004; Stiewe and Putzer, 2000). It is widely believed that
induction of apoptosis by E2Fs eliminates cells that have ac-
quired a sporadic, oncogenic mutation in Rb or a regulator of
Rb function. The work we present here now demonstrates
both a specificity of E2F1 transcription control reflecting this bi-
partite function as well as a role for the PI3K/Akt survival pathway
to regulate the E2F1 apoptotic program.
We have demonstrated that growth factor stimulated activa-
tion of PI3K and Akt, but not Mek, blocks E2F1 induced apopto-
sis (Hallstrom and Nevins, 2003). Akt is a serine/threonine kinase
that phosphorylates several cellular proteins either inhibiting
their proapoptotic or enhancing an antiapoptotic activity. Some
of these cell-cycle or apoptotic regulatory Akt targets like
p27KIP1, BAD, and Caspase-9 are inactivated by Akt phosphor-
ylation (Cardone et al., 1998; Datta et al., 1997; del Peso et al.,
1997). Akt phosphorylation also degrades p53 by activating its
inhibitor Mdm2, inhibits Forkhead transcription of proapoptotic
targets, and promotes activation of NF-kB transcription of pro-
survival targets by inducing degradation of IkB, an inhibitor of
NF-kB function (Ashcroft et al., 2002; Ogawara et al., 2002).
Interestingly, Akt can indirectly inhibit E2F1 transcriptional activ-
ity by phosphorylating TopBP1 promoting its binding to and
repression of E2F1 (Liu et al., 2006).
While the E2F1 targets that are not affected by PI3K include
genes that function in cell proliferation, the PI3K regulated
E2F1 target genes are clearly distinct (Figure 6). Importantly,
we show that several of these are required for the ability of
E2F1 to induce apoptosis. One of these genes, AMPKa2, has
been shown previously to function in sensing and responding
to conditions of cellular energy deprivation, and other work has
shown that AMPKa2, but not AMPKa1, is induced by hypoxia
and glucose deprivation (Laderoute et al., 2006). Moreover,
AMPKa2, the catalytic kinase subunit of the AMPK trimer, can
induce growth arrest by promoting p53 phosphorylation (Jones
et al., 2005). Furthermore, AMPKa2 is a phosphorylation target
of the tumor suppressor gene LKB1, indicating a potential
interplay between the Rb/E2F, PI3K, and LKB1/AMPK tumor
suppressor pathways.
The balance between cell death and proliferation is often dis-
rupted in the oncogenic process leading to tumor expansion
because of failure of the normal cell death process. Indeed, we
find that the two categories of E2F1 target genes, proliferation
and apoptosis, are expressed in a mutually exclusive fashion
in breast and ovarian cancers in a manner that correlates withpredicted PI3K activity and patient clinical outcome. Based on
the predicted activation state, PI3K may be pivotal in regulating
this different transcriptional output by E2F1 in tumors. Our anal-
ysis demonstrates that patients with tumors that poorly express
the PI3K-repressed E2F1 target genes generally show a signifi-
cantly poorer prognosis than patients expressing higher levels
of these genes. Whether this distinction arises from differences
in apoptosis induction by E2F1 and, if so, whether apoptosis
can be restored by chemically inhibiting PI3K signaling remains
to be determined. We do find that activation of the AMPKa2
gene by AICAR, an AMP analog, accentuates apoptosis in con-
nection with deregulated E2F1 activity, suggesting a potential
strategy for therapeutic intervention. Biguanide AMPK activators
like metformin, currently used to treat diabetes, may potentially
be interesting candidates for cancer treatment (Hardie, 2007;
Motoshima et al., 2006). Additionally, one might anticipate that
in those tumors exhibiting decreased expression of AMPKa2
as well as the other E2F1 apoptotic target genes, inhibition of
the PI3K signaling pathway might also have therapeutic benefit
by restoring expression of these genes.
EXPERIMENTAL PROCEDURES
Cell Culture and Apoptosis Assays
U2OS and IMR90 cells were passaged in DMEM media containing 10% fetal
calf serum. REF52 (rat embryo fibroblast) cells were passaged in DMEMmedia
containing 5% fetal calf and 5% bovine calf serum. Cells to be infected were
brought to quiescence by plating (3 3 105 cells/60 mm plate) in serum-
containing media for 24 hr and then washing and replacing with 0.25%
serum-containing media. Cells were deprived of serum for 48 hr before infect-
ing with adenovirus. Cells to be infected in serum-containing media were
plated 24 hr prior to virus infection. Cell numbers were determined prior to
infection to infect with equal adenoviral multiplicities. Floating and adherent
cells were harvested at 40 hr postinfection, fixed with formaldehyde, stained
with a PE-conjugated antibody that binds to active, cleaved caspase-3, and
analyzed by FACS following the manufacturer’s protocol (BD PharMingen).
LY294002 and AICAR were purchased from Sigma and final concentrations
used were 50 uM (LY294002) and 125 uM (AICAR).
Adenovirus and Retrovirus Infection
Adenovirus expressing hemagglutin (HA)-tagged E2F1 and control adenovirus
not expressing any gene have been described previously (Hallstrom and
Nevins, 2003). Morris Birnbaum kindly provided adenovirus expressing rat
Myc-tagged AMPKa2. Retroviruses were packaged using Plat-A cells for
infection in human derived cells (Morita et al., 2000). Plasmid DNA (4 mg)
was transfected into the packaging line (in 1200 ml DMEM) using Fugene 6
transfection reagent (Roche). After 24 hr, another 1000 ml media was added
to the cells and incubated another 20 hr. Supernatant was filtered through
0.45 mm HT Tuffryn membrane low-protein-binding filter syringes (44 hr post-
transfection) and used to infect target cells. Polybrene (8 mg/ml) was included
to assist infection efficiency. Drug selection was started 24 hr postinfection.
Drug selection concentrations for U2OS cells were 1.25 mg/ml puromycin
and 1.0 mg/ml for IMR90 cells. shRNA-targeting vectors were purchased
from OpenBiosystems. The specific constructs and sequences used in this
study can be found in the Supplemental Data.
RNA Isolation and Gene Expression Analysis
RNA was isolated from adenovirus-infected cells 40 hr postinfection using an
RNeasyMidi Kit fromQIAGEN. 10 mgmRNAwas submitted to the DukeMicro-
array core for analysis with the RAE230a Affymetrix rat chip. We extracted
MAS5 and RMA (robust multiarray average) data from the .CEL files using
the ‘‘R’’ programming set (http://www.r-project.org). Rat (RAE230A) probe
IDs of interest were converted to correlating Human U133A IDs (the platform
of the cancer data sets) using Resourcerer at compbio.dfci.harvard.edu.Cancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc. 19
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Repression of E2F1 Apoptosis by PI3K in CancerFigure 5. Analysis of E2F1 Target Gene Expression in Human Cancers
(A) The expression values of PI3K-repressed and -nonrepressed E2F1 target genes were extracted from a breast cancer expression study (GSE1456). These
genes and tumor samples were organized using unsupervised hierarchical clustering. The class identity of clustered genes is displayed in the red/green bar
to the right; PI3K-nonrepressed E2F1 targets are green while the PI3K-repressed E2F1 targets are indicated with red (see [D]). Breast tumors are segregated
into two major groups defined by expression levels of the PI3K-repressed and -nonrepressed E2F1 targets. The first class, marked above with the red shaded
clustering, expresses high levels of the PI3K-repressed genes and low levels of the PI3K-nonrepressed genes. The second class, labeled with a green shaded
clustering, display an inverse relationship with the other clustered set of breast tumors. These tumors express low levels of PI3K-repressed E2F1 targets and
generally express high levels of nonrepressed targets. PI3K gene expression signatures were used to predict the activation state of the PI3K pathway (blue
representing low activity, red representing high activity) and are displayed below the clustered genes as a colored bar. Breast cancer tumor stages are displayed
below the PI3K prediction colored bar. The two groups of breast cancer patients were designated either ‘‘low apoptotic’’ or ‘‘high apoptotic’’ based on relative
expression levels of the PI3K-repressed E2F1 target genes and were plotted according to patient survival in the Kaplan-Meier survival curve to the right. The data
indicate that patients expressing lower relative levels of the PI3K-repressed (apoptotic) target genes display a significantly poorer prognosis.
(B) Similar analysis as described in (A) was performed on a different breast cancer data set (GSE4922).
(C) Ovarian tumors (GSE3149), as seen in the breast cancer tumors, are also segregated into two major groups defined by high or low expression levels of the
PI3K-repressed and -nonrepressed E2F1 targets. PI3K gene expression signatures were used to predict the activation state of the PI3K pathway (blue
representing low activity, red representing high activity) and are displayed below the clustered genes. Ovarian tumor stages are displayed below the PI3K20 Cancer Cell 13, 11–22, January 2008 ª2008 Elsevier Inc.
Cancer Cell
Repression of E2F1 Apoptosis by PI3K in CancerNext, the human probe IDs corresponding to the E2F1 apoptotic and prolifer-
ative genes were extracted out of the breast and ovarian cancer data sets us-
ing an internal bioinformatics merging tool. We used the GeneCluster program
(http://rana.lbl.gov/EisenSoftware.htm) to cluster our RMA data in an unsuper-
vised, hierarchical fashion and visualized the heat map using Java Treeview
(available from the same location). Genes and tumors were clustered using av-
erage linkagewith the uncentered correlation similarity metric. A signature rep-
resentative of PI3-kinase activation was developed as previously described
(Bild et al., 2006). Standard Kaplan-Meier mortality curves and their signifi-
cance levels were generated for clusters of patients with similar patterns of
oncogenic pathway deregulation using GraphPad Prism software. The
GATHER bioinformatics tool has been described and can be found online at
http://gather.genome.duke.edu/.
Real-Time PCR
We used the QuantiTect SYBR Green RT-PCR kit from QIAGEN according to
manufacturer’s specifications for our quantitative real-time PCR. Each exper-
imental condition used 100 ng of RNA for reverse transcription, and RT-PCR
Figure 6. Control of E2F1 Proliferation and Apoptotic Gene Regula-
tion by the PI3K/Akt Pathway
Growth factor stimulation activates a number of different intercellular signaling
pathways that intersect to control cell fate outcomes like proliferation and
apoptosis. For example, activation of Cyclin D/Cdk4 kinase complexes result
in phosphorylation of Retinoblastoma (Rb), releasing it from E2F1 transcription
factor repression. E2F1 is then free to transcriptionally activate genes that
promote proliferation and apoptosis. Cells are at least partially able to distin-
guish ‘‘normal’’ from oncogenic stimulated growth through the activation of
the PI3K/Akt signaling pathway, which can inhibit the activation of proapop-
totic target genes and apoptosis by E2F1. Cells with PI3K-blocked apoptosis
are then capable of completing normal proliferation without apoptotic inter-
ference.and was performed in triplicate and normalized against expression of Rat or
Human GAPDH expression levels. Analysis was done with an ABI Prism
7900HT detection system (Applied Biosystem) according to the manufac-
turer’s protocol.
Protein Immunoblotting Analysis
REF52 cells were harvested 40 hr postinfection into microfuge tubes and
resuspended in boiling sample buffer. Equivalent amounts of protein were
separated by SDS-PAGE, transferred to an Immobilon-P (Millipore) membrane
and blocked in T-TBS containing 5% nonfat dry milk. Blots were then
incubated with primary antiserum (1:1000) at room temperature for 4 hours,
washed three times with T-TBS buffer, and then incubated with the appropri-
ate secondary antiserum (1:2000) for one hour at room temperature. Blots
were processed using the ECL system (Amersham). Antiserum against
E2F1 (c-20) was purchased from Santa-Cruz Biotechnology for immunoblot
analysis.
Supplemental Data
The Supplemental Data include two supplemental figures and one supplemen-
tal table and can be found with this article online at http://www.cancercell.org/
cgi/content/full/13/1/11/DC1/.
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